T-Cell Lymphoma Forum 2012

 
 
 

 

Consortium data sheds light on ENKL in North America

Jen Smith Read Article
Published: 02/10/12

smith_sonali_240.jpg
Sonali M. Smith, MD

The paucity of data on extranodal NK T-cell lymphoma (ENKL) in North America has led to a poor understanding of this patient population, according to a speaker at the 4th Annual T-cell Lymphoma Forum. But the North American T-cell Consortium—a collaborative effort that includes 18 academic centers in the US and British Columbia—could change that. In fact, an early analysis of consortium data has already provided new insights into patient characteristics . . . [Read Article]

Drug shows activity in aggressive PTCL

Jen Smith Read Article
Published: 02/08/12

Pro_Barbara_240.jpg
Barbara Pro, MD

A phase 2 study suggests romidepsin can elicit durable responses in patients with recurrent peripheral T-cell lymphomas (PTCLs). Study subjects had failed prior systemic therapies and had “very aggressive” disease, according to investigators. But treatment with romidepsin provoked a response rate of 29% and a median response duration of 17 months. Barbara Pro, MD, of Fox Chase Cancer Center in Philadelphia, discussed these results at the 4th Annual T-cell Lymphoma Forum. [Read Article]

New prognostic index for ATL

Jen Smith Read Article
Published: 02/06/12

katsuya_hiroo_MD_240.jpg
Hiroo Katsuya, MD

Japanese investigators have developed a new prognostic index for patients with acute and lymphoma-type adult T-cell leukemia/lymphoma (ATL). The group’s research indicated that 5 factors can predict survival in this patient population, including Ann Arbor stage, performance status, age, serum albumin, and soluble interleukin-2 receptor (sIL-2R). Hiroo Katsuya, MD, of Fukuoka University, discussed the importance of these factors and the research that identified them at the 4th Annual . . . [Read Article]

Results suggest new approach to SCT in TCLs

Jen Smith Read Article
Published: 02/03/12

Nickelsen_Maike_240.jpg
Maike Nickelsen, MD

An EBMT study has shown that the outcome of transplantation remains poor for most T-cell lymphoma patients. But the results also point to an approach that may prove more effective. The retrospective study assessed the outcomes of autologous stem cell transplant (auto-SCT) and allogeneic SCT (allo-SCT) in patients with T-cell lymphomas. The researchers found that survival rates were low regardless of transplant type. Auto-SCT patients had solid responses initially . . . [Read Article]

Is the US running too many T-cell lymphoma trials?

Jen Smith Read Article
Published: 02/02/12

Younes_Anas_240.jpg
Anas Younes, MD

The US currently has 284 open clinical trials enrolling patients with T-cell lymphomas, a fact that is actually detrimental to this patient population, according to an expert in the field. Anas Younes, MD, of MD Anderson Cancer Center in Houston, presented this perspective at the 4th Annual T-cell Lymphoma Forum, which took place January 26-28. Dr Younes noted that there are 361 clinical trials worldwide that are currently accruing patients with T-cell lymphomas. Of those . . . [Read Article]

Decitabine and HDAC inhibitors are potent combo

Jen Smith Read Article
Published: 02/01/12

Marchi_Enrica_MD_PhD_at_poster_walk_credit_Larry_Young_better_220.jpg
Enrica Marchi, MD, PhD,
discusses her research at
the T-cell Lymphoma Forum
Credit: Larry Young

Preclinical research indicates the hypomethylating agent decitabine is synergistic with a range of HDAC inhibitors, but it is particularly potent when combined with belinostat or romidepsin. Investigators tested decitabine plus panobinostat, vorinostat, romidepsin, or belinostat in T-cell lines. And they assessed decitabine plus belinostat in a mouse model of cutaneous T-cell lymphoma (CTCL). Enrica Marchi, MD, PhD, presented the results at the 4th Annual T-cell Lymphoma Forum. [Read Article]

Risk of lymphomas after breast cancer

Jen Smith Read Article
Published: 01/31/12

Largent_Joan_PhD.jpg
Joan A. Largent, PhD

An industry-run study has quantified breast cancer survivors’ risk of developing non-Hodgkin lymphomas (NHLs). The researchers found an elevated risk of NHL in breast cancer survivors when compared to the general population. T-cell lymphomas (TCLs) were the most common subtype observed, followed by breast lymphomas, and anaplastic large-cell lymphomas (ALCLs). Joan A. Largent, PhD, of Allergan, Inc., presented these findings at the 4th Annual T-cell Lymphoma Forum. [Read Article]

The state of ATL research in Japan

Jen Smith Read Article
Published: 01/31/12

Watanabe_Toshiki_MD_PhD.jpg
Toshiki Watanabe, MD, PhD

Japanese researchers are gaining new insights into the role of HTLV-1 in adult T-cell leukemia (ATL), according to a speaker at the 4th Annual T-cell Lymphoma Forum. Toshiki Watanabe, MD, PhD, of The University of Tokyo, reported data on the number of HTLV-1 carriers in Japan and described the creation of a national material bank comprised of samples from HTLV-1-infected individuals. He also discussed a pair of Japanese studies that provide key findings in ATL, one of which . . .  [Read Article]

New gene therapy for NK-cell neoplasms

Jen Smith Read Article
Published: 01/30/12

Karube_Kennosuke.jpg
Kennosuke Karube, MD

A novel gene therapy for NK-cell neoplasms may be on the horizon, according to research presented at the 4th Annual T-cell Lymphoma Forum. The study showed that the tumor suppressor gene FOXO3 is functionally specific to NK-cell neoplasms. And this suggests the gene could be useful in developing safer, more effective therapy for aggressive NK-cell leukemia and nasal type extranodal NK/T-cell lymphoma, said Kennosuke Karube, MD, of Aichi Cancer Center Research . . . [Read Article]

Study describes role of race in MF/SS

Jen Smith Read Article
Published: 01/30/12

Imam_Muhammad_MD_2_final.jpg
Muhammad Imam, MD

For years, studies have shown that black individuals develop mycosis fungoides (MF) and Sézary syndrome (SS) more often than white individuals. Now, a group of investigators has found evidence to suggest that blacks are also more likely to present with MF or SS at a younger age and with greater disease severity than whites. However, these factors did not translate to a significant difference in short-term survival between black patients and white patients.  [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}